Cytek launches new immunoprofiling assay

By Will Morton, The Science Advisory Board contributing writer

October 7, 2021 -- Cytek Biosciences has launched a 25-color immunoprofiling assay optimized for its flagship Aurora cell analysis systems.

The new assay includes reagents and tools to simplify workflows from sample preparation to data analysis and offers researchers an efficient way to obtain relevant data and shorten the time from biological question to answer, Cytek said.

Cytek's reagent assay is furnished with protocols for sample preparation, staining, and acquisition, as well as experiment and analysis templates to streamline workflow and improve laboratory efficiency, the company said.

The assay can help distinguish different subsets of immune cells, including regulatory, naive, activated, memory, and effector T cells; naive and memory B cells; early, mature, and terminal NK cells; and nonclassical and classical monocytes. Reagent kits function as a backbone upon which users can add additional markers and expand the panel, Cytek said.

In addition, to support the new 25-color immunoprofiling assay, Cytek has released an 18-color cFluor reagent kit that can be used with seven reagents from other suppliers. The 25-color assay has been optimized and titrated for use with seven Brilliant Violet reagents available from BioLegend for analyzing human peripheral blood mononuclear cells and whole blood on Cytek's full-spectrum systems.

Cancer-linked genes help tumors evade immune system
Tumors have more genetic tricks for escaping detection by the immune system than previously thought, according to a new study published on September 17...
CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...
Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter